The Institute for Clinical and Economic Review will conduct an insurance profit analysis for two new additive therapies cardiovascular disease.
Patients Rising NOW offers the following comments on ICER’s May 22nd draft report, “Deflazacort, Eteplirsen, and Golodirsen for Duchenne Muscular Dystrophy.” Our comments about the draft report are organized below…
Their kids have a rare and fatal disease. ICER President Dr. Steve Pearson believes Duchenne moms shouldn't get a "vote" on their kids' treatment.
ICER. What is it? Who is it? Who put them in charge of my children’s health care? I ask this question – urgently – because Thursday, this group called ICER…
Citing its impact on “health care insurance costs,” the Institute for Clinical and Economic Review has issued its dreaded insurance profitability “alert” for two new treatments for peanut allergies. ICER’s report encourages insurance companies to deny coverage and impose substantial barriers for patients seeking access to the treatments.
ICER uses quality-adjusted life years to calculate value and determine health care access. Here are 5 ways that the QALY formula is bad for patients.
The Institute for Clinical and Economic Review and its controversial “one-size-fits-all” value framework are a direct threat to patients living with rare diseases, an independent report warns.
To fix its broken value framework, ICER should stop using the QALY, or quality-adjusted life year, in its value framework and cost assessments.
Patients living with migraine need access to effective treatments. ICER has begun its process of evaluating treatments for acute migraine.
The Institute for Clinical and Economic Review (ICER) is floating a power grab at the Food and Drug Administration to deny patients access to innovation.